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Background: Chandraprabha vati is a classical Ayurvedic formulation, markedly used for mitigation of
Prameha, which correlates in many ways with obesity, metabolic syndrome and diabetes mellitus.
Objective: The present study was aimed to investigate effect of Chandraprabha vati in experimentally-
induced hyperglycemia and lipid proﬁle alterations.
Materials and methods: Antidiabetic effect of Chandraprabha vati was studied in ﬁfty ﬁve Wistar rats.
Graded doses of Chandraprabha vati (50,100 and 200mg/kg) were administered orally for 7 days to normal
and alloxan-hyperglycemic rats (65 mg/kg, intravenously), and to glucose loaded normal rats for oral
glucose tolerance test (OGTT). Fasting plasma glucose levels were assessed on different time intervals
alongwith plasma cholesterol and triglycerides. Metformin (500mg/kg, orally) was used as standard drug.
Results: Chandraprabha vati did not cause any signiﬁcant reduction in plasma glucose levels of normal
rats (p > 0.05) but normalized the impaired glucose tolerance at 60 and 120 min (p < 0.05ep < 0.001) in
OGTT when compared to vehicle control. In alloxan-hyperglycemic rats, administration of Chandraprabha
vati (200 mg/kg) signiﬁcantly reduced plasma glucose at 3 h, 12 h, 3rd day and 7th day (p < 0.01
ep < 0.001) along with reduction in cholesterol and triglycerides levels (p < 0.01ep < 0.001) when
compared to diabetic control group. The effects were comparable with metformin.
Conclusions: Chandraprabha vati exhibited anti-hyperglycemic effect and attenuated alterations in lipid
proﬁle. The results support the use of Chandraprabha vati for correction of Prameha in clinical practice.
© 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is categorized as a metabolic disease, char-
acterized by hyperglycemia which results from defects in insulin
secretion, insulin action or both. The hyperglycemia in turn
damages many of the body's systems leading to diabetic compli-
cations, which further exacerbate the diabetic condition and affect
the quality of life. The increasing worldwide incidence of diabetes
mellitus in adults constitutes a global public health burden. It is
predicted that by 2030, India, China and USA will have the largest
number of people with diabetes [1]. Despite appreciable progress
made in the management of diabetes mellitus using conventional. Wanjari).
ary University, Bangalore.
alore and World Ayurveda Foundat
es/by-nc-nd/4.0/).antidiabetic management strategies, the search for products of
natural origin for control of diabetes mellitus continues. The
World Health Organization (WHO) has also long back recom-
mended that this practice should be encouraged, especially in
countries where access to conventional treatment of diabetes
mellitus is not adequate [2]. Many herbal formulations are widely
used in treatment of diabetes [3] and many more are being
evaluated for their effectiveness in controlling diabetes. Ayurveda
and other traditional systems of medicines describe number of
plants/minerals and/or their formulations for treatment of
diabetes.
Chandraprabha vati (CPV) is an Ayurvedic formulation available
in classical vati form. It is used in Ayurvedic system of medicine for
various indications [4] such as Vibandha (Constipation), Anaha
(Distension of abdomen due to obstruction to passage of urine and
stools), Shula (Colicky Pain), Granthi (Cyst), Pandu (Anaemia),ion. Publishing Services by Elsevier B.V. This is an open access article under the CC
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Arsha (Hemorrhoids), Arbuda (Tumor), Mutraghata (Urinary
obstruction), Antra-Vrddhi (Hernia), Kati shula (Lower backache),
Kustha (Diseases of skin), Kandu (Itching), Plihodara (Disorder of
spleen, ascites associated with splenomegaly), Bhagandara (Fistula-
in-ano), Dantaroga (Dental disease), Netraroga (Eye disorder), Aru-
chi (Tastelessness), Mandagni (Impaired digestive ﬁre), Striroga
(Gynaecological disorders), Artava Ruja (Dysmenorrhoea), Shukra
Dosha (Vitiation of semen), Daurbalya (Weakness) and Prameha.
Chandraprabha vati has got very remarkable effect in mitigation of
Prameha which correlates in many ways with obesity, metabolic
syndrome and diabetes mellitus (Madhumeha) [5]. It contains 37
herbomineral ingredients (Table 1) [4]. Most of these ingredients
exhibited both glucose and lipid lowering activities in experimental
studies. The ingredients like Acorus calamus [6,7], Cyperus rotundus
[8], Phyllanthus niruri [9], Tinospora cordiofolia [10], Curcuma longa
[11], Berberis aristata [12], Piper longum [13,21], Coriandrum sativum
[14], Terminalia chebula [15], Terminalia belerica [16], Embelica ofﬁ-
cinalis [17], Embelia ribes [18], Zingiber ofﬁcinale [19], Piper nigrum
[20], Hordeum vulgare [22], Ipomoea turpethum [23], Cinnamomum
zeylanicum [24] and Asphaltum punjabianum [25] showed remark-
able antidiabetic effects in several studies. Most of the important
plant constituents of this formulation [15,21,24,25] including
Commiphora wightii (Guggulu) [26] have demonstrated hypolipi-
demic effect. In experimental studies, Suresh et al. [27] demon-
strated curative effect of Chandraprabha vati on streptozotocin-
induced diabetes. Despite the long history of use of Chan-
draprabha vati in diabetes and antidiabetic and lipid lowering effect
of constituent plants, the systematic scientiﬁc studies are still
lacking to delineate and validate its therapeutic utility in control-
ling diabetes. Hence, the present study demonstrates the effect of
Chandraprabha vati on alloxan-induced hyperglycemia and alter-
ations of lipid proﬁle in rats.2. Materials and methods
2.1. Drugs and chemicals
Chandraprabha vati was procured from Indian Medicines Phar-
maceutical Corporation Ltd., Ramnagar, Uttarakhand, India. Alloxan
monohydrate was procured from CDH Chemicals, India while
metformin was gift sample from ZIM Laboratories Ltd., Nagpur,
India. Glucose, cholesterol and triglycerides estimation kits (ERBA-Table 1
Composition of Chandraprabha vati [4].
1. Chandraprabha (Karpura) (Sub. Ext.) 3 g
2. Vacha (Rz.) 3 g
3. Musta (Rz.) 3 g
4. Bhunimba (Kiratatikta) (Pl.) 3 g
5. Amruta (Guduchi) (St.) 3 g
6. Daruka (Devadaru) (Ht. Wd.) 3 g
7. Haridra (Rz.) 3 g
8. Ativisha (Rt. Tr.) 3 g
9. Darvi (Daruharidra) (St.) 3 g
10. Pippalimula (Pippali) (Rt.) 3 g
11. Chitraka (Rt.) 3 g
12. Dhanyaka (Fr.) 3 g
13. Haritaki (P.) 3 g
14. Bibhitaka (P.) 3 g
15. Amalaki (P.) 3 g
16. Chavya (St.) 3 g
17. Vidanga (Fr.) 3 g
18. Gajapippali (Fr.) 3 g
19. Sunthi (Rz.) 3 g
Sub. Ext. e Sublimed extract, Rz. e Rhizome, Pl. e Plant (W
trunk, St. e Stem, Rt. e Root, Fr. e Fruit, P. e Pericarp, Lf. e
Concretion, Exd. e Exudate.Mannheim) were procured from Transasia Bio-Medicals Pvt. Ltd.,
Mumbai, India. Quercetin was procured from Sigma Aldrich, USA.
Tannic acid and all other reagents used in the experiments were of
analytical grade and procured from Qualigens Fine Chemicals Ltd.,
Mumbai, India.
2.2. Standardization of Chandraprabha vati
Chandraprabha vati was ﬁrst standardized as per standard pro-
cedures/guidelines [28,29]. Various physicochemical parameters
viz. total ash, acid-soluble and -insoluble ash, water-soluble and
-insoluble ash, alcohol and water-soluble extractive values, loss on
drying and pH were determined accordingly.
2.3. Phytochemical screening and quantitative estimation of
phytoconstituents
Chandraprabha vati (10 g powder formulation) was macerated
with 100 ml water for 48 h and ﬁltered through Whatman ﬁlter
paper no. 1. The ﬁltrate was used for preliminary phytochemical
screening [29] and quantitative estimation of phytoconstituents.
The total phenolic content of aqueous extract of CPV was deter-
mined by Folin and Ciocalteu's reagent colorimetric assay spec-
trometrically [30] and expressed as gram of tannic acid equivalents
per 100 g of powder drug while total ﬂavonoid content was
measured by aluminium chloride colourimetric assay [31] and
expressed as gram of quercetin equivalents per 100 g of powder
drug.
2.4. Animals
Healthy adult Wistar albino rats (200e250 g) of either sex be-
tween 2 and 3 months of age were used for the investigations. They
were housed in group in polypropylene cages, maintained under
standard conditions (12 h light and dark cycle; temperature
25 ± 1 C; humidity 40e60%) and fed with standard rat pellet diet
(Ashirwad brand, Chandigarh, India) and puriﬁed water ad libitum.
Experiments were performed at pharmacology division of National
Research Institute for Ayurveda-Siddha Human Resource Devel-
opment (NRIASHRD), Gwalior, India in accordance with the
guidelines of Committee for the Purpose of Control and Supervision
of Experiments on Animals (CPCSEA), Ministry of Environment and
Forests, and Climate change, New Delhi after seeking approval from20. Maricha (Fr.) 3 g
21. Pippali (Fr.) 3 g
22. Makshika dhatu bhasma (Makshika) 3 g
23. Yava kshara (Yava) (Pl.) 3 g
24. Sarji Kshara (Svarjiksara) 3 g
25. Saindhava lavana 3 g
26. Sauvarchala lavana 3 g
27. Vida lavana 3 g
28. Trivrit (Rt.) 12 g
29. Danti (Rt.) 12 g
30. Patraka (Tejapatra) (Lf.) 12 g
31. Tvak (St.Bk.) 12 g
32. Ela (Sukamaila) (Sd.) 12 g
33. Vamshalochana (Vamsa) (S.C.) 12 g
34. Lauha bhasma 24 g
35. Sita 48 g
36. Silajatu 96 g
37. Guggulu (Exd.) 96 g
hole), St. e Stem, Ht. Wd. e Heart wood, Rt. Tr. e Root
Leaf, St. Bk. e Stem bark, Sd. e Seed, S.C. e Silicacious
Table 2
Physico-chemical evaluation of formulation of Chandraprabha vati.
Standardization parameters Value
Ash analysis (% w/w)
1. Ash content (Total ash) 23.39 ± 0.32
2. Acid soluble ash 18.55 ± 0.17
3. Acid insoluble ash 4.84 ± 0.20
4. Water soluble ash 18.54 ± 0.17
5. Water insoluble ash 13.33 ± 1.06
Extractive value (Maceration process)
1. Water soluble (% w/w) 39.57 ± 0.79
2. Alcohol soluble (% w/w) 22.77 ± 0.48
Moisture content (Loss on drying) (% w/w) 0.106 ± 0.002
pH (1% aqueous solution) 5.47 ± 0.04
Values are expressed as mean ± SEM; n ¼ 3.
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2.5. Determination of human equivalent dose of Chandraprabha
vati
For administration purpose, human equivalent dose of CPV for
rats was determined on basis of surface area ratio as described in
standard textbook [32]. The calculated doses were approximately
50 and 100 mg/kg body weight of rats. So the three doses of CPV i.e.
50, 100 and 200 mg/kg body weight were tested to plot complete
dose response curve in the present study. As per Ayurvedic litera-
ture, the suggested vehicle/adjuvant (anupana) for CPV is water,
milk, gungily powder. Hence, the powdered drug was suspended in
distilled water using 4% gum acacia and suspension was adminis-
tered orally to animals by intragastric feeding needle.
2.6. Acute toxicity study
Acute oral toxicity study was carried out to determine the safe
dose by acute toxic class method as per Organization for Economic
Co-operation and Development (OECD) 423 guidelines [33]. The
overnight fasted rats (n ¼ 3) were orally administered CPV in the
limit test dose of 2000 mg/kg and observed continuously for
behavioural, neurological and autonomic proﬁles for 2 h and after a
period of 24, 72 h and thereafter up to 14 days for any lethality,
moribund state or death. The limit test was repeated in another
group of rats (n ¼ 3) for conﬁrmation and toxic class of LD50
determination.
2.7. Pharmacological evaluation
2.7.1. Effect of CPV on plasma glucose in healthy control rats
Rats were divided in ﬁve different groups (5 rats/group). Vehicle
treated group received 4% gum acacia in distilled water while CPV
was administered in dose of 50, 100 and 200 mg/kg, orally. Refer-
ence standard treated group received metformin (500 mg/kg,
orally). The treatments were given for 7 days. Blood was withdrawn
from fasted rats (10 h) through retro orbital sinus [34] on 0, 1, 3,
12 h, 72 h (3rd day) and 168 h (7th day) and clear plasma was
obtained after centrifugation at 3000 rpm for 10 min. Fasting
plasma glucose levels were estimated using a Glucose Oxida-
seePeroxidase glucose estimation kit using semiautomated clinical
chemistry analyser (Microlab 300, Vital Scientiﬁc-Merck).
2.7.2. Effect of CPV on oral glucose tolerance test (OGTT)
On day 7, the oral glucose tolerance test [35,36] was performed
in the same groups of above-mentioned euglycemic rats. Glucose
(4 g/kg) was fed orally, 1 h after the administration of drugs/vehicle.
Blood was withdrawn at 0, 30, 60 and 120 min of glucose admin-
istration and fasting plasma glucose levels were estimated as
mentioned above.
2.7.3. Effect of CPV on alloxan-induced hyperglycemia and lipid
proﬁle
2.7.3.1. Induction of hyperglycemia. The hyperglycemia was
induced by single dose of alloxan monohydrate. It was prepared
freshly in normal saline which was acidiﬁed to increase stability of
alloxan [37]. Immediately after preparation, it was administered
intravenously through tail vein at a dose of 65 mg/kg [38,39].
Glucose solution (5% w/v), 1e2 ml per rat, was immediately
administered intragastrically to alloxan treated rats in order to
prevent transient hypoglycemia. Plasma glucose was estimated in
fasted (10 h) rats 48 h after the administration of alloxan as
mentioned above.The rats exhibiting fasting plasma glucose levels more than
250 mg/dl were considered hyperglycemic (diabetic) and
continued for further investigations.
2.7.3.2. Experimental design. Rats were divided in six different
groups (5 rats/group). Non-diabetic healthy control group received
normal saline intravenously while diabetic vehicle control group
received alloxan and vehicle of the CPV (4% gum acacia in distilled
water, 5 ml/kg). Test drug treated groups received CPV (50, 100 and
200 mg/kg) while standard treated group received metformin
(500mg/kg). The vehicle or drug treatments were given daily orally
for 7 days. Blood was withdrawn from fasted rats (10 h) on 0, 1, 3,
12 h, 72 h (3rd day) and 168 h (7th day) and fasting plasma glucose
levels were estimated at all intervals while plasma levels of total
cholesterol and triglycerides were also estimated at 168 h (7th day)
by commercially available kits.
2.8. Statistical analysis
The data were analyzed with one-way ANOVA and two-way
ANOVA, wherever applicable followed by Bonferroni multiple
comparison post hoc test. A statistical difference of p < 0.05 was
considered signiﬁcant in all cases.
3. Results
3.1. Standardization of formulation
The physico-chemical characterization of CPV is mentioned in
Table 2.
3.2. Qualitative Phytochemical screening
Qualitative phytochemical tests of CPV showed the presence of
steroids, ﬂavonoids, alkaloids, tannins and phenolic compounds,
while carbohydrates, proteins, amino acids, and glycosides were
absent.
3.3. Quantitative estimation of phytoconstituents
The total phenolic content of CPV was found to be 6.19 g tannic
acid equivalents/100 g of powdered drug while its total ﬂavonoid
content was found to be 3.28 g quercetin equivalents/100 g of
powdered drug.
3.4. Acute toxicity study
Acute oral toxicity studies revealed that the CPV was safe up to a
dose level of 2000 mg/kg of body weight (limit test) and LD50 was
Table 3
Effect of CPV on plasma glucose in euglycemic rats.
Groups Plasma glucose (mg/dl)
0 h 1 h 3 h 12 h Day 3 Day 7
Vehicle 105 ± 3.79 111 ± 4.93 107 ± 6.31 113 ± 2.82 117 ± 3.63 111 ± 5.57
CPV 50 116 ± 2.66ns 113 ± 2.48ns 110 ± 3.94ns 111 ± 4.37ns 110 ± 4.28ns 105 ± 5.14ns
CPV 100 119 ± 6.38ns 122 ± 9.46ns 111 ± 6.37ns 110 ± 4.36ns 108 ± 4.06ns 95 ± 8.86ns
CPV 200 99 ± 6.87ns 94 ± 7.84ns 96 ± 7.63ns 106 ± 5.51ns 123 ± 9.63ns 93 ± 4.55ns
MET 500 122 ± 9.47ns 114 ± 6.15ns 103 ± 6.24ns 125 ± 3.31ns 118 ± 4.18ns 101 ± 4.21ns
Values are expressed as mean ± SEM, (n ¼ 5); Doses are expressed as mg/kg body weight.
ns e non signiﬁcant.
CPV e Chandraprabha vati; MET e Metformin.
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actions or moribund state were observed up to the end of the study
period.
3.5. Effect of CPV on plasma glucose in healthy control rats
Two-way ANOVA did not show any signiﬁcant effect of CPV on
plasma glucose levels in healthy control rats (p> 0.05). Post hoc test
indicated that CPV at 50, 100 and 200 mg/kg did not exhibit sig-
niﬁcant reduction in the plasma glucose in healthy control rats
(Table 3). The standard drug metformin (p > 0.05) also did not in-
ﬂuence plasma glucose level.
3.6. Effect of CPV on oral glucose tolerance test (OGTT)
Two-way ANOVA showed that CPV showed signiﬁcant inﬂuence
on OGTT after glucose load administration (Table 4) and CPV (50,
100 and 200 mg/kg) normalized the impaired glucose tolerance
and showed observable reduction in serum glucose levels from 60
to 120 min after glucose load. The standard drug, metformin
signiﬁcantly normalized the impaired glucose tolerance compared
to control (Table 4) and showed reduction in the plasma glucose
from 60 min onwards.
3.7. Effect of CPV on hyperglycemia, cholesterol and triglycerides
Two-way ANOVA showed that alloxan administration caused
signiﬁcant (p < 0.001) hyperglycemia in rats at 0, 1, 3, 12 h, 3rd and
7th day after conﬁrmation of hyperglycemia when compared to
euglycemic rats. Post hoc test indicated that administration of CPV
at 50 and 100 mg/kg signiﬁcantly (p < 0.01ep < 0.001, wherever
applicable) reduced the plasma glucose levels in alloxan-induced
hyperglycemic animals only at day 3 and 7 while dose of 200 mg/
kg signiﬁcantly (p < 0.01ep < 0.001, wherever applicable) reduced
the plasma glucose levels in alloxan-induced hyperglycemic ani-
mals at 3 h, 12 h, day 3 and day 7. The standard drug, metformin
(500 mg/kg) also showed signiﬁcant reduction in the plasma
glucose levels in alloxan-induced hyperglycemic rats 3 h onwardsTable 4
Effect of CPV on oral glucose tolerance test (OGTT).
Groups Plasma glucose (mg/dl)
0 min 30 min 60 min 120 min
Vehicle 105 ± 3.79 175 ± 4.92 196 ± 6.74 162 ± 5.29
CPV 50 109 ± 3.36ns 171 ± 2.48ns 178 ± 3.22* 143 ± 2.89*
CPV100 103 ± 6.01ns 166 ± 2.48ns 174 ± 4.35@ 140 ± 6.25@
CPV 200 105 ± 3.48ns 161 ± 4.09ns 163 ± 2.92# 129 ± 3.15#
MET 500 101 ± 4.21ns 160 ± 4.18ns 160 ± 4.84# 112 ± 5.49#
Values are mean ± SEM, (n ¼ 5); Doses are expressed in mg/kg body weight.
ns e nonsigniﬁcant, *p < 0.05, @p < 0.01, #p < 0.001 compared to vehicle.
CPV e Chandraprabha vati; MET e Metformin.(Table 5). The effect of metforminwas comparable to higher dose of
CPV (p > 0.05).
One-way ANOVA showed that alloxan administration signiﬁ-
cantly inﬂuenced plasma levels of total cholesterol and tri-
glycerides at 168 h (7th day) as compared to healthy control rats
(Fig. 1). Post hoc test indicated that alloxan-hyperglycemic rats
exhibited raised cholesterol and triglycerides levels (p < 0.001)
compared to healthy control rats. CPV at 100 and 200 mg/kg
signiﬁcantly (p < 0.01ep < 0.001) prevented rise in cholesterol and
triglycerides levels while lower dose CPV (50 mg/kg) did not have
signiﬁcant inﬂuence on triglycerides and cholesterol levels (Fig. 1).4. Discussion
The present study was designed and conducted to evaluate the
inﬂuence of CPV on blood glucose proﬁle and lipid proﬁle in
alloxan-induced hyperglycemic rats and to scientiﬁcally validate its
traditional use in diabetes.
The determined physico-chemical constants of the formulation
were as per the previous studies [40]. The toxicity study of CPV in
the limit test dose of 2000 mg/kg revealed neither toxicity of any
nature nor moribund stage. This indicated that the CPV has no
toxicity at such high dose and considered to be safe for adminis-
tration. The calculated human equivalent dose of CPV for rats is
approximately 50e100 mg/kg which is fairly lower (20 times) than
that of the limit test dose of 2000 mg/kg at which there was no
toxicity or moribund state. Hence, the study was conducted with
initial human equivalent dose of 100 mg/kg. Based on the results
the doses lower (50 mg/kg) and higher (200 mg/kg) than initial
dose were used for further evaluation.
In order to study the inﬂuence on blood glucose in hypergly-
cemic conditions, the effect of CPV was ﬁrst tested for its hypo-
glycemic effect in euglycemic animals. The results of the
investigations in euglycemic rats revealed that treatment with CPV
for seven days did not show any signiﬁcant decrease in the basal
glucose levels in healthy control rats. Similarly, metformin, a
standard anti-hyperglycemic agent, did not affect the basal plasma
glucose levels. This is in accordance with the reports which
demonstrated that metformin does not produce hypoglycemia in
non-diabetic state [41]. These investigations suggest that CPV, per
se, has no hypoglycemic effect. However, in the previous study [27],
it is mentioned that CPV showed some hypoglycemic effect at 6 h of
administration in euglycemic rats. It is possible that the doses used
in the present study (50e200 mg/kg) are very less than that of the
previous study which used nearly 10 times higher doses (0.5e1.5 g/
kg).
In glucose loaded normal rats, signiﬁcant suppression of plasma
glucose was observed at 120 min after administration of the CPV.
This indicates that CPV was able to normalize the impaired glucose
tolerance in glucose loaded normal rats. Similar effect was also
observed for metformin.
Table 5
Effect of CPV on plasma glucose in alloxan-induced hyperglycemia.
Groups 0 h 1 h 3 h 12 h Day 3 Day 7
Healthy control 115.6 ± 4.11 111.4 ± 4.94 107.8 ± 6.31 113.6 ± 2.82 117 ± 3.63 111.8 ± 5.57
Vehicle 417.6 ± 10.07* 396 ± 7.27* 381.4 ± 10.15* 356.2 ± 4.04* 345.4 ± 9.01* 310.6 ± 8.41*
CPV 50 414.4 ± 6.65ns 378.4 ± 4.80ns 380.2 ± 4.5ns 354 ± 4.40ns 305.2 ± 7.95@ 233 ± 10.46#
CPV 100 406.6 ± 6.52ns 372.4 ± 8.04ns 366.6 ± 5.73ns 348.6 ± 6.82ns 283.8 ± 6.72# 164 ± 7.51#
CPV 200 418 ± 11.84ns 370.6 ± 12.07ns 340.8 ± 6.41@ 318.2 ± 6.45@ 246 ± 10.54# 142.2 ± 5.90#
MET 500 402.6 ± 8.91ns 367 ± 14.72ns 336 ± 4.88# 312.6 ± 6.37# 243.2 ± 10.75# 132.2 ± 11.11#
Values are expressed as mean ± SEM, (n ¼ 5); Doses are expressed in mg/kg body weight.
ns e nonsigniﬁcant, *p < 0.001 compared to healthy control, @p < 0.01, #p < 0.001 compared to vehicle.
CPV e Chandraprabha vati; MET e Metformin.
Fig. 1. Effects of CPV on lipid proﬁle (A), Cholesterol (B) Triglycerides. Results are
expressed as mean ± SEM, (n ¼ 5); Doses are expressed in mg/kg body weight.
*p < 0.001 compared to healthy control, @p < 0.01, #p < 0.001 compared to vehicle.CPV
e Chandraprabha vati; MET e Metformin
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exhibited signiﬁcant hyperglycemia. Alloxan-induced hyperglyce-
mia simulates to type I diabetes (insulin dependent diabetes mel-
litus). It has two distinct pathological effects: selective inhibition of
glucose-induced insulin secretion through speciﬁc inhibition of
glucokinase, the glucose sensor of the beta cell; and generation of
free radicals through redox cycling between alloxan and its
reduction product dialuric acid, resulting in the selective necrosis of
beta cells. These two effects can be attributed to selective cellular
uptake and accumulation of alloxan by the beta cell [37,42].
Excessive hepatic glycogenolysis and gluconeogenesis associated
with decreased utilization of glucose by tissues is the fundamental
mechanism underlying hyperglycemia in the diabetic state [43]. As
the hyperglycemia induced by alloxan falls under category of
reversible diabetes and may reverse after a week [44], the effect of
the CPV in hyperglycemic rats was studied during 7 days treatment.
The results of the investigations in alloxan-induced hyperglycemic
rats showed long term administration of CPV was effective to
decrease plasma glucose levels. The standard drug, metformin also
showed anti-hyperglycemic effect. This indicated that CPV hasantihyperglycemic effect. From the investigations, it appeared that
the effect of CPV is dependent on the dose. Low doses of CPV (50
and 100 mg/kg) showed signiﬁcant decrease in glucose levels from
3rd day onwards while higher dose of 200 mg/kg exhibited
decrease within 3 h of administration similar to metformin, the
standard drug, which also showed anti-hyperglycemic effect. As a
biguanide, metformin reduces both fasting and postprandial
glucose levels mainly by inhibiting hepatic gluconeogenesis and
glucose output. Metformin also facilitates peripheral uptake, uti-
lisation and metabolism of glucose, provided some endogenous
insulin is present. Thus, metformin reduces both fasting and post-
prandial hyperglycaemia by promoting insulin-mediated periph-
eral glucose utilisation and metabolism in adipose tissues and
skeletal muscles through up-regulation of glucose transporters
[45,46]. It is not clear as to how CPV caused the reduction in hy-
perglycemia. It is possible that CPV, like metformin, might be
improving insulin action at the cellular level or enhancing the ac-
tion of insulin or by increasing the glucose metabolism or glucose
homeostasis in the diabetic animals. Therefore, the mechanism
underlying this effect needs to be studied. As stated earlier CPV
contains various ingredients which have shown antidiabetic
property in various experimental studies. These plant ingredients
showed antidiabetic activity by various mechanisms viz. insulin
sensitizing activity [6] or regeneration of pancreatic beta cells [12],
antioxidant action [8,18] or inﬂuencing insulin resistance [11] or by
altering the carbohydrate metabolism [10] or insulin-like effect via
peripheral glucose utilization. Thus, the antihyperglycaemic effect
of the CPV may be attributed to the cumulative effect of these
constituent plants.
Many times diabetes is associated with hyperlipidemia [47]. It is
well documented that there is elevation of plasma lipid concen-
tration in diabetics [48]. In the present investigation, alloxan-
induced hyperglycemic rats also exhibited rise in the total choles-
terol and triglycerides levels when compared to untreated diabetic
group. It is well known that under normal circumstances insulin
activates the enzyme lipoprotein lipase which hydrolyses the tri-
glycerides. Insulin deﬁciency results in the failure to activate the
enzymes thereby resulting in hypertriglyceridemia. CPV treated
groups showed decrease in cholesterol and triglycerides. This may
be due to the presence of hypocholesterolemic plants constituents
and minerals like guggulu (Commiphora wightii), musta (C. rotun-
dus), shilajit (A. punjabianum), etc. present in CPV that may act as
inhibitors for some enzymes such as hydroxyl methyl glutaryl CoA
reductase, which participates in cholesterol synthesis or reduces
the absorption of cholesterol from intestine [49]. The reduction in
the triglycerides levels indicates that CPV might be enhancing the
action of insulin and thereby normalizing the action of lipoprotein
lipase. The present study adds antihyperlipidemic effect of CPV in
diabetic rats compared to previous study [27] and suggests effec-
tiveness of CPV in controlling diabetes along with lipid
abnormalities.
M.M. Wanjari et al. / Journal of Ayurveda and Integrative Medicine 7 (2016) 144e150 149Further, phytochemical investigation of CPV revealed the pres-
ence of steroids, ﬂavonoids, alkaloids, tannins and phenolic com-
pounds. The quantitative phytochemical studies showed a fair
amount of phenolic and ﬂavonoids in the CPV. Various phenolic
compounds were reported to have anti-hyperglycemic activity and
antidiabetic activities [50,51]. So, the presence of the active moi-
eties in the individual plants might be contributing important role
in attenuation of hyperglycemia and hyperlipidemia.
The present study still has certain limitations like lack of esti-
mation of insulin levels and histopathology of pancreas. The results
of the present investigations in fact suggest that the drugs like
Chandraprabaha vati may provide promising effects against type II
diabetes. Hence, further studies are needed for assessment in
chronic models of type II diabetes viz. Streptozotocin-Nicotinamide
induced diabetes or fructose induced diabetes.5. Conclusions
The present investigation suggest Chandraprabha vati exhibits
the anti-hyperglycemic effect and attenuates the glycation associ-
ated elevation in the lipid proﬁle. This further supports the use of
Chandraprabha vati for correction of Prameha in clinical practice.Acknowledgements
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